NCT02352649View on ClinicalTrials.gov

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2017

Conditions
Peripheral Nerve Injury
Interventions
DRUG

Neovasculgen

Sponsors

Lead Sponsor

Artgen Biotech
All Listed Sponsors
collaborator

Kazan Federal University

OTHER

lead

Artgen Biotech

OTHER

NCT02352649 - Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury | Biotech Hunter | Biotech Hunter